Biomimetic manganese-based theranostic nanoplatform for cancer multimodal imaging and twofold immunotherapy

Zhao, Yanjie; Pan, Yuanwei; Zou, Ke‐Long; Lan, Zhou; Cheng, Guowang; Mai, Qiuying; Cui, Hao; Meng, Qian‐Fang; Chen, Tongkai; Rao, Lang; Ma, Limin; Yu, Guang‐Tao

doi:10.1016/j.bioactmat.2022.04.011

Cited by 44 publications

(42 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CD45 + immune cells were enriched using the CD45 Positive Selection Kit (STEMCELL, 18945) according to the instructions before staining. Flow antibodies that we used refer to a previous article [ 27 ].…”

Section: Methodsmentioning

confidence: 99%

PFC@O2 Targets HIF-1α to Reverse the Immunosuppressive TME in OSCC

Lan

Zou

Cui

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

As a typical hallmark of solid tumors, hypoxia affects the effects of tumor radiotherapy, chemotherapy, and photodynamic therapy. Therefore, targeting the hypoxic tumor microenvironment (TME) is a promising treatment strategy for cancer therapy. Here, we prepared an Albumin Human Serum (HSA)-coated perfluorocarbon (PFC) carrying oxygen (PFC@O2) to minimize OSCC hypoxia. The results showed that PFC@O2 significantly downregulated the expression of HIF-1α and the number of M2-like macrophages in vitro. Furthermore, PFC@O2 effectively inhibited the growth of oral squamous cell carcinoma (OSCC) and reduced the proportion of negative immunoregulatory cells, including myeloid-derived suppressor cells (MDSCs) and M2-like macrophages of TME in a 4-nitroquinoline N-oxide (4NQO)-induced mouse model. Conversely, the infiltration of CD4+ and CD8+ T cells was significantly increased in TME, suggesting that the anti-tumor immune response was enhanced. However, we also found that hypoxia-relative genes expression was positively correlated with CD68+/CD163+ TAMs in human tissue specimens. In summary, PFC@O2 could effectively inhibit the progression of OSCC by alleviating hypoxia, which provides a practical basis for gas therapy and gas synergistic therapy for OSCC.

show abstract

Section: Methodsmentioning

confidence: 99%

PFC@O2 Targets HIF-1α to Reverse the Immunosuppressive TME in OSCC

Lan

Zou

Cui

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mn 2+ catalyzes H 2 O 2 into ·OH for CDT, leading to the activation of cGAS-STING but also directly acts on STING, inducing the secretion of type-I interferons, proinflammatory cytokines and chemokines. Additionally, PTT and CDT-mediated ICD of tumor cells can further enhance antitumor immunity via exposure to calreticulin (CRT), high mobility group protein B1 (HMGB1) and adenosine triphosphate (ATP) [ 140 ].…”

Section: Several Breakthroughs Of Nanometallic Materials In Cancer Im...mentioning

confidence: 99%

Metal ions and nanometallic materials in antitumor immunity: Function, application, and perspective

Shen

Fang

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

The slightest change in the extra/intracellular concentration of metal ions results in amplified effects by signaling cascades that regulate both cell fate within the tumor microenvironment and immune status, which influences the network of antitumor immunity through various pathways. Based on the fact that metal ions influence the fate of cancer cells and participate in both innate and adaptive immunity, they are widely applied in antitumor therapy as immune modulators. Moreover, nanomedicine possesses the advantage of precise delivery and responsive release, which can perfectly remedy the drawbacks of metal ions, such as low target selectivity and systematic toxicity, thus providing an ideal platform for metal ion application in cancer treatment. Emerging evidence has shown that immunotherapy applied with nanometallic materials may significantly enhance therapeutic efficacy. Here, we focus on the physiopathology of metal ions in tumorigenesis and discuss several breakthroughs regarding the use of nanometallic materials in antitumor immunotherapeutics. These findings demonstrate the prominence of metal ion-based nanomedicine in cancer therapy and prophylaxis, providing many new ideas for basic immunity research and clinical application. Consequently, we provide innovative insights into the comprehensive understanding of the application of metal ions combined with nanomedicine in cancer immunotherapy in the past few years. Graphical Abstract

show abstract

“…Nanomaterials assembled with in situ self-assembly strategy as a starting point are widely used in drug delivery and cancer therapy (48)(49)(50). They can selectively respond to physiological changes or TME by targeting the tumor extracellular matrix, tumor neovascularization, cell membranes with specific receptors, and other structures (51,52). M1-TAMs are thought to suppress tumor growth, in contrast to M2-TAMs.…”

Section: In Situ Self-assemblymentioning

confidence: 99%

“…The latter’s functions promote tumor cell invasion, growth and metastasis. Therefore, modulating the tumor immunosuppressive microenvironment (TIME) by remodeling TAM subpopulations can help achieve immune normalization ( 53 – 55 ). However, achieving the goal of complete tumor eradication through cancer immunotherapy strategies with only single TAM polarization is difficult.…”

Section: Self-assembled Multifunctional Nanomaterialsmentioning

confidence: 99%

Nanomaterials: A powerful tool for tumor immunotherapy

et al. 2022

View full text Add to dashboard Cite

Cancer represents the leading global driver of death and is recognized as a critical obstacle to increasing life expectancy. In recent years, with the development of precision medicine, significant progress has been made in cancer treatment. Among them, various therapies developed with the help of the immune system have succeeded in clinical treatment, recognizing and killing cancer cells by stimulating or enhancing the body’s intrinsic immune system. However, low response rates and serious adverse effects, among others, have limited the use of immunotherapy. It also poses problems such as drug resistance and hyper-progression. Fortunately, thanks to the rapid development of nanotechnology, engineered multifunctional nanomaterials and biomaterials have brought breakthroughs in cancer immunotherapy. Unlike conventional cancer immunotherapy, nanomaterials can be rationally designed to trigger specific tumor-killing effects. Simultaneously, improved infiltration of immune cells into metastatic lesions enhances the efficiency of antigen submission and induces a sustained immune reaction. Such a strategy directly reverses the immunological condition of the primary tumor, arrests metastasis and inhibits tumor recurrence through postoperative immunotherapy. This paper discusses several types of nanoscale biomaterials for cancer immunotherapy, and they activate the immune system through material-specific advantages to provide novel therapeutic strategies. In summary, this article will review the latest advances in tumor immunotherapy based on self-assembled, mesoporous, cell membrane modified, metallic, and hydrogel nanomaterials to explore diverse tumor therapies.

show abstract

Biomimetic manganese-based theranostic nanoplatform for cancer multimodal imaging and twofold immunotherapy

Cited by 44 publications

References 49 publications

PFC@O2 Targets HIF-1α to Reverse the Immunosuppressive TME in OSCC

PFC@O2 Targets HIF-1α to Reverse the Immunosuppressive TME in OSCC

Metal ions and nanometallic materials in antitumor immunity: Function, application, and perspective

Nanomaterials: A powerful tool for tumor immunotherapy

Contact Info

Product

Resources

About